DEXCOM INC

Company Overview

Dexcom Inc. is a Healthcare company in the Medical Devices (Medical Equipment) industry focused on continuous glucose monitoring (CGM) systems and related disposables. Its business is highly recurring and disposables‑driven (disposables ≈97% of revenue in Q2 2025), with growth coming from customer additions, new product clearances (G7 15 Day) and the Stelo OTC launch for earlier‑stage glucose care. The U.S. accounts for roughly 73% of sales, margins have compressed recently due to production yield and mix issues, and the company is investing heavily in R&D and an Ireland manufacturing build‑out while carrying outstanding convertible notes. Management cites seasonal patterns (Q1 deductible resets), pricing/rebate headwinds, FX exposure as it expands internationally, and healthy operating cash flow and liquidity for near‑term funding.

Executive Compensation Practices

Given Dexcom’s operating model, executive pay is likely weighted toward equity and performance‑based incentives: the company already records material share‑based compensation and cites higher compensation in R&D and SG&A. Short‑term incentives are expected to track commercial metrics (revenue, operating income/margins, disposable sensor volume and customer additions), while long‑term awards will be tied to strategic milestones such as FDA clearances, product launches, manufacturing scale‑up and total shareholder return. Capital structure items (convertible notes, potential dilution) and cash flow/capex needs for the Ireland facility will influence how much compensation is cash versus equity and the vesting/target levels for long‑term awards. Regulatory and reimbursement dynamics (rebates, channel mix) also create measurable KPIs that management can link to bonus triggers.

Insider Trading Considerations

Insider transactions at Dexcom are likely event‑driven: earnings releases, FDA clearances, product launches (e.g., Stelo, G7) and manufacturing ramp milestones are common catalysts for insider buys/sells. High reliance on equity compensation (RSUs/options) and periodic vesting/exercise schedules can produce predictable insider selling for tax and liquidity needs; watch for clustered Form 4 activity following vesting or option exercises. The upcoming convertible note maturities, seasonality in revenue, and supply‑chain/production yield developments are additional triggers that may prompt insider trades or disclosure; check for 10b5‑1 trading plans and Section 16 filings. Finally, the Healthcare/Medical Devices regulatory environment (FDA, reimbursement and anti‑kickback rules) imposes heightened disclosure expectations and blackout periods that can constrain executive trading.